Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI

Exclusion Criteria

• •Patient is under consideration for or has undergone a successful bone marrow transplant (BMT)
• •Patient refuses or is unable to complete all screening evaluations
• •Pregnant or lactating patient
• •Patient has received an investigational drug within 30 days prior to study enrollment
• •Patient has been previously treated with rhASB
• •Patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly confound study results or decrease study compliance
• •The patient has clinically significant spinal cord compression
• •The patient has known hypersensitivity to rhASB or to components of the active or placebo test solutions